COMPASS study (Cardiovascular Outcomes for People Using Anticoagulation Strategies study) done by the researchers from the McMaster University found that a treatment to prevent further heart complications with aspirin and rivaroxaban drugs combination is superior when compared with aspirin alone in individuals with the vascular disease. The study involved 27,395 patients with stable atherosclerotic vascular disease from 33 countries. The study was intended to find out superior treatment to prevent stroke, heart attack and death between the rivaroxaban drug and the combination of rivaroxaban and aspirin drugs.
Researchers compared rivaroxaban (2.5 mg dose twice-daily) combined with aspirin (100 mg dose once-daily) to rivaroxaban (5 mg dose twice daily) or aspirin (100 mg once-daily). The study findings show rivaroxaban and aspirin drug combination reduces cardiovascular events and the drug combination treatment is better than only rivaroxaban or only aspirin medication. Improvement in the stable coronary artery disease or peripheral artery disease (PAD) and increase the chances of a major bleeding (mainly in gastroenterological) were found with the drug combination treatment. The study also shows the drug combination treatment is superior to aspirin for the risk of limitation of blood flow to a limb or losing limbs among peripheral artery disease (PAD) patients. The risk of major cardiovascular events reduces by 19 percent with aspirin drug. But rivaroxaban and aspirin drugs combination reduces
But aspirin drug alone is better compared with rivaroxaban drug alone in preventing stroke, heart attack, cardiovascular death or limb events. Lead authors of the study were Dr. John W. Eikelboom, Associate Professor, Hematology & Thromboembolism, Department of Medicine, McMaster University, Hamilton, Ontario, Canada. The study findings were published on November 10, 2017, in The Lancet. Title of the article was "Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomized, double-blind, placebo-controlled trial."
A study done by the Australian experts found a big increase in the number of patients with coronary artery disease complications among young men and women and also across all age groups without heart disease risk factors such as high blood pressure or hypertension, high blood sugar glucose levels or diabetes, high cholesterol levels, obesity or higher body mass index (BMI) and tobacco usage.
Experts reviewed 695 heart attack patients at the Royal North Shore Hospital, St Leonards, Sydney, Australia between 2006 and 2014. Researchers found 132 individuals with heart diseases but without heart disease risk factors. The study has found an increase in heart disease events from 11 percent during 2006 to 27 percent in 2014 among young men and women without heart disease risk factors.
But the researchers could not able to identify the causes of the life-threatening coronary artery disease (plaque build up in the arteries or the development of atherosclerosis) in people without heart disease risk factors.
This study was funded by the University of Sydney and the Heart Research Australia. Senior author of the study was Dr. Gemma Figtree, Professor in Medicine, the University of Sydney and an interventional cardiologist at the Royal North Shore Hospital, (a public teaching hospital) at St Leonards, Sydney, Australia. The study findings were published on July 13, 2017, in the European Journal of Preventive Cardiology. Title of the article was "Increasing proportion of ST elevation myocardial infarction patients with coronary atherosclerosis poorly explained by standard modifiable risk factors."
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. Published article is not a medical advice by the OWNER of "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.